Annual report 2009: first successful collaboration with the biotechnology company ThromboGenics.
Specialising in the research and development of treatments for vascular disease and cancer, ThromboGenics wanted its 2009 annual report to focus on the development of its new microplasmin programme which could be a decisive advance in the treatment of certain patients suffering from diseases of the retina.
